Large differences in clinical response to selective serotonin reuptake inhibitors (SSRIs) are observed in depressive patients with different genotypes. Quantification of these differences is needed to decide if genetic testing prior to antidepressant treatment is useful. We conducted a systematic review of the literature on the influence of polymorphisms in the serotonin transporter gene (SERTPR (or 5-HTTLPR) and STin2) on SSRI response. Studies were identified by the use of MEDLINE, EmBase and PsycINFO, references of articles, reviews and information from pharmaceutical companies. Nine studies assessing the influence of SERTPR or STin2 on treatment response were included. Outcome was expressed as the percentage of decrease in depression score (HAM-D or MADRS) or as the percentage of responders (Z50% reduction on the depression scale). Both study methodologies and study outcomes showed large heterogeneity. Weighted mean decreases in depression score for patients with the s/s, s/l and l/l genotypes were 35.4, 46.3 and 48.0% at week 4, respectively, and 53.9, 54.6 and 48.3% at week 6. Among Caucasian patients, both mean decrease in depression score and response rate were lowest in the s/s group, while among Asian patients, results were inconsistent. Weighted response rates were 36.1% for the 10/12 genotype of the STin2 polymorphism and 80.7% for the 12/12 genotype (v 2 ¼ 27.8, Po0.001) (only Asians). The available evidence points to a less favourable response to SSRI treatment among Caucasian patients with the SERTPR s/ s genotype and among (Asian) patients with the STin2 10/12 genotype. In view of the scarcity and heterogeneity of the studies, however, current information is insufficiently reliable as a basis for implementing genetic testing in the diagnostic work-up of the depressive patient.
Selective serotonin reuptake inhibitors (SSRIs) are used for the treatment of a number of conditions including depression. 1, 2 It has been previously suggested that the response to SSRIs is, at least partly, under genetic control.
3, 4 Two polymorphisms have been proposed as possible explanations for the observed interindividual differences in SSRI response: an insertion/deletion polymorphism in the promoter region (SERTPR, also named 5-HTTLPR) and a variable number of tandem repeats (VNTR) polymorphism in intron 2 (STin2) of the serotonin transporter gene, which is the primary target for antidepressants. 1, 3, 5 Since approximately one-third of all depressive patients do not express an adequate positive response to initial treatment with antidepressants, and the duration of medication needed to evaluate treatment effect is long (4-6 weeks), 6 it might be cost-effective to incorporate testing on genetic polymorphisms affecting treatment response into the diagnostic work-up of the depressive patient. In order to analyse the costeffectiveness of such a procedure, valid and reliable quantifications of the differences in clinical response to SSRIs between depressive patients with different genotypes are needed. We carried out a systematic review of the literature regarding the clinical response to SSRIs in depressive patients in relation to genetic polymorphisms in the serotonin transporter gene (SERTPR and STin2).
Methods

Search strategy
A literature search was conducted in Medline, EmBase and PsycINFO to identify studies on SSRI treatment in relation to the SERTPR and STin2 polymorphisms in the serotonin transporter gene. This search was performed in November 2002 for all papers published from 1966 and updated on 2, January 2003 and 29, April 2003. The keywords 'depression AND serotonin transporter AND gen*, depression AND medication AND gen*, antidepressants AND genotype' were used. Moreover, references of retrieved articles and relevant previously published reviews were hand-searched to identify additional studies. Finally, the five pharmaceutical companies producing SSRIs were kindly requested to provide any unpublished information on the subject.
Studies were included if they assessed the association between response on SSRIs and a genetic polymorphism of the serotonin transporter gene in patients diagnosed with Major Depressive Disorder according to DSM criteria. Studies were excluded from the review if study outcome was not assessed as a reduction on a depression scale, if the study population had been used to analyse the same polymorphism more than once, and if the article was not written in English, German, French, Spanish, Italian, Norwegian, Swedish, Danish or Dutch. Authors were contacted in case of confusion about potentially overlapping study populations.
Data extraction
Data were collected from all included studies by two investigators independently (KS and LS). The following study characteristics were extracted: inclusion and exclusion criteria, polymorphism (type and frequency of occurrence), treatment (type of SSRI, dose and dose escalation schedule, duration, presence of pindolol addition), blinding procedures (blinded for clinical course of depression or for genotype), evaluation of confounding (tested for differences at baseline or confounders included in analyses) and population descriptives, that is number of patients, sex, age and ethnicity. Outcomes were extracted for three points in time: at baseline, and at 4 and 6 weeks after the start of medication. Differences in extracted data were resolved by discussion. In case of any unresolved dispute, a third investigator (MP) was available for consultation.
Analyses
In order to enhance the comparability of individual study results, we transformed mean depression scores on the Hamilton Rating Scale for Depression or the Montgomery and Ashberg Depression Rating Scale as presented in the individual studies into mean decrease on HAM-D or MADRS if possible. This was achieved by comparing the mean scores with the mean baseline scores for the different genotypes. When specific values were not available elsewhere in the article, we estimated mean HAM-D or MADRS scores from the presented figures. Additionally, we transformed the number of responders into the percentage of responders. Differences of genotype frequencies for Caucasians and Asians were tested by the use of one-way ANOVA. Deviations from HardyWeinberg equilibrium were analysed for all included studies using the w 2 test. Pooled estimates for treatment effect weighted for individual study size were calculated for all patients and for Caucasians and Asians separately. Differences in response rates between genotypes were tested by use of a w 2 test. Relative risks (RR) were then calculated for the pooled response rates using the random effects model.
Results
In all, 12 studies on SSRI response and genotype were identified by use of the literature search. Further hand search and requests for information from SSRIproducing companies yielded no additional studies. One study was excluded from the review because it addressed a manic switch possibly related to antidepressant use rather than a reduction on a depression scale. 7 Another study 8 was excluded because the study population had already been published in another study that was included in the review. 9 A third study was excluded because HAM-D scores were not reported in the text or in a figure. 10 Finally, nine studies were included in the review. 9, [11] [12] [13] [14] [15] [16] [17] [18] Patient characteristics Table 1 shows the characteristics of the studies included in the review. Seven studies addressed the SERTPR polymorphism, 9, [11] [12] [13] [14] [15] [16] one study analysed the influence of the STin2 polymorphism 18 and one study addressed the SERTPR polymorphism as well as the STin2 polymorphism. 17 Studies varied with respect to type of drug (fluoxetine, fluvoxamine and paroxetine), dose (variation between and within studies), duration of treatment at outcome evaluations (2-18 weeks), the inclusion of in-or outpatients, bipolar patients or delusional patients, and the evaluation of potential confounders. The mean age in all studies was similar (range: 44.7-54.2), except for one study that only included patients over 60 years old, 15 and was not reported in another study. 13 Four studies included Asian patients, 12, 14, 17, 18 three other studies only included Italian patients 9, 11, 16 and two studies did not explicitly report the ethnicity of the patients but probably included predominantly Caucasian subjects. 13, 15 The population size of the included studies varied between 51 and 121 patients, and studies reporting the sex of the subjects included more women except for one study. 12 All studies excluded patients with other serious Axis I or II disorders, other serious medical disorders and patients using psychotropic drugs during the last 2 or 4 weeks before inclusion in the study. Some studies also excluded patients with a serious suicide risk, with a history of substance abuse or with pregnancy. 12, 13, 15, 17 Study outcomes Table 2 shows frequencies of genotypes and study outcomes at baseline, for 4 and 6 weeks. Outcome measures included mean decrease in HAM-D or MADRS score and percentage responders for various Depression, genetics and treatment: a systematic review KM Smits et al In two studies, a number of patients were also taking pindolol as an augmentation to SSRI treatment. 9, 16 In one of these studies, it was not possible to extract data on patients without pindolol addition. 9 
SERTPR
Frequencies of the different genotypes of SERTPR were reported in six studies. [11] [12] [13] [14] 16, 17 Caucasian patients appeared to have different gene frequencies as compared to Asian patients. Frequencies for the s/s genotype varied from 21.6 to 28.3% in the studies predominantly including Caucasian patients; 11, 13, 16 for the Asian studies these frequencies varied between 55.6 and 60.0% (F ¼
12,14,17 The mean decrease in HAM-D score was reported by five studies. [11] [12] [13] 15, 16 One of these studies reported this outcome measure, however, solely for patients carrying an s-allele compared to patients carrying the l/l genotype. 15 The mean decrease in HAM-D and MADRS scores per genotype varied largely between studies (eg, mean 4-week decrease in HAM-D/ MADRS scores for the l/l genotype: range 9.8-70.6%). The weighted mean decrease in HAM-D/ MADRS score after 4 weeks was 35.4% for the s/s genotype, 46.3% for the s/l genotype and 48.0% for the l/l genotype. [11] [12] [13] [14] 16 For 6 weeks, these values were 53.9, 54.6, and 48.3%, respectively. 13, 14, 16 Within the studies comprising Caucasians only, however, the s/s genotype showed a less favourable response at both 4 weeks (weighted mean decrease in HAM-D score: 26.2 % (s/s) vs 51.5% (s/l) and 50.2% (l/l)) 9,11,15 and 6 weeks (40.7% (s/s) vs 56.0% (s/l) and 52.4% (l/l)). 13, 16 The results of another study combining the s/s and s/l genotype pointed into the same direction. 15 For Asians, pooled estimates could only be calculated for 4 weeks (mean decrease: 39.2% (s/s), 39.3% (s/l) and 42.4% (l/l)).
12,14 At 6 weeks, a mean decrease in MADRS score was observed of 65.3% (s/s), 51.4% (s/ l) and 18.0% (l/l). 14 The percentage of responders, in all studies defined as a 50% decrease on the HAM-D or MADRS scale, was reported by five studies, 9,12,14,15,17 one of which only reported these values including subjects receiving pindolol augmentation 9 and another reported these values only after 2 weeks of medication. 15 The one study comprising Caucasian patients showed poorer response rates at 6 weeks of medication for patients with the s/s (70.4%) and s/l (75.5%) genotype than those with the l/l genotype (87.5%) (P ¼ 0.029). 9 RRs could not be calculated for these response rates because the number of responders was not mentioned in the article. The picture was reversed for Asians; the pooled response rates at 6 weeks were 81.6% for the s/s genotype, 58.2% for the s/l genotype and 33.3% for the l/l genotype (w 2 ¼ 16.56,
Po0.001).
14, 17 The RR for being a responder when having the s/s genotype compared with the l/l genotype was 2.48 (95% CI 0.30-32.32). For the s/l vs the l/l genotype, the RR was 1.70 (95% CI 0.24-11.76).
However, another study among Asian patients, reporting response rates after 4 weeks of medication, found 29.2% responders among those with the s/s genotype, 27.8% among those with the s/l genotype and 69.2% among those with the l/l genotype.
12 RR for the s/s vs the l/l genotype is 0.42 (95% CI 0.25-0.70) and OR for s/l vs l/l is 0.40 (95% CI 0.21-0.76).
Deviations from Hardy-Weinberg equilibrium were analysed using a w 2 test. All studies appeared to be in Hardy-Weinberg equilibrium except for one (w 2 ¼ 6.01; P ¼ 0.05). 12 The weighted mean decrease in HAM-D/MADRS score after 4 weeks for the studies in Hardy-Weinberg equilibrium solely was 38.1% for the s/s genotype, 50.0% for the s/l genotype and 46.9% for the l/l genotype. 11, 13, 14, 16 
STin2
The STin2 polymorphism was addressed by two studies, both among Asian patients. The number of patients with the 10/10 genotype was very small in both studies (1 and 2) . 17, 18 The pooled response rate for the 10/12 genotype was 36.1 and 80.7% for the 12/ 12 genotype (0 of 3 for the 10/10 genotype) (w 2 ¼ 27.8, Po0.001). 17, 18 The RR for the 10/12 genotype vs the 12/12 genotype is 0.46 (95% CI 0.07 -3.05). The mean decrease in MADRS score (reported in one study) was equal for patients with the 10/12 and 12/12 genotype (46.6 vs 48.4% at 4 weeks, and 55.5 vs 55.5% at 6 weeks). 18 All studies on STin2 were in HardyWeinberg equilibrium.
Discussion
This review systematically summarises the available empirical evidence concerning the influence of two polymorphisms in the serotonin transporter gene, SERTPR and STin2, on the response to SSRI treatment in patients diagnosed with Major Depressive Disorder. We were able to retrieve nine articles reporting on either SERTPR or STin2. Although all eight studies addressing the SERTPR polymorphism reported at least some influence of genotype on the response to SSRIs, the overall picture appeared to be more diffuse, since the reported effects showed opposite directions. Ethnicity might, however, have played a role in determining the direction of the effect. In Caucasian patients, response to SSRIs seemed less favourable for patients with the s/s genotype than for those with the s/l and l/l genotypes. On the other hand, among Asian patients effects in both directions were observed. Patients with the 10/12 variant of the STin2 polymorphism showed a less favourable response to SSRI treatment than those with the 12/12 variant. However, data of only two studies were available, both among Asian patients.
Depression, genetics and treatment: a systematic review 10 Rausch JL (2002) 11 Yoshida K (2002) 12 Zanardi R (2001) 13 Pollock BG (2000) 14 Zanardi R (2000) 9 Smeraldi E (1998) 15 Kim DK (2000) 16 Ito K (2002) 17 The studies conducted among Caucasian patients report an s/s SERTPR genotype frequency around 25%. This is in accordance with frequencies previously reported in studies on this polymorphism. 4 On the other hand, Asian studies report a frequency of the s/s genotype of around 57%. It is unclear how this ethnic difference in the distribution of the s-allele relates to the difference in influence on the effect of SSRIs. After analysis, one study 12 showed a significant deviation from the Hardy-Weinberg equilibrium, even though the article from this study mentioned no deviations.
Frequencies
Several versions of the Hamilton Rating Scale for Depression were used in the individual studies. It is possible that the version that was used or the experience of the interviewers using the HAM-D have influenced depression scores, 19 which might have hampered the comparison of depression scores among individual studies.
It should be emphasized that, even though studies were only included if they met our inclusion criteria, there was considerable heterogeneity between individual studies with respect to population characteristics, type of intervention, outcome measurement and validity. Although all studies only included patients if diagnosis was confirmed according to DSM-IV criteria, differences regarding the inclusion of inpatients or patients with bipolar depression could have affected individual study results by influencing treatment effect. A manic relapse in patients with bipolar depression could lead to an apparent 'improvement' in depression scores and therefore alter study outcome. 20 Likewise, differences in diagnosis could affect interpatient comparability. Different SSRIs, fluoxetine, fluvoxamine and paroxetine, were used in the included studies and some studies used multiple dosages of SSRIs or did not stipulate the dosage to be used. Using different SSRIs and varying dosages impedes the comparison of study results. Subjects did not all receive an identical treatment and nonresponse could be caused by the received dosage that was too low rather than the genotype of interest. Furthermore, it is unclear whether the possible influence of genotype is equal for each of the SSRIs. 1 One study was designed to increase the dose of the SSRI after 5 weeks if patients did not respond to the treatment. 15 This strategy could reduce the differences in response between the genotypes by the increase in dose. Although such a strategy is appropriate in daily psychiatric practice, it limits the ability to gain a valid quantitative insight into the mechanisms of SSRI response. Likewise, the administration of pindolol in addition to SSRI treatment may have distorted study results.
A distortion of individual study results could also have been caused by the assumption of a dominant model for the s-allele as was done in one of the studies. 15 Even though research in human cell lines suggests a dominant s-allele 4 and this model was confirmed in some studies, 9, 12 other study results point to a model in which the l-allele functions as the dominant allele. 11, 13, 16 Larger samples are probably needed to determine which allele brings about a dominant influence. 9 Information on blinding procedures and correction methods was lacking in some studies. Although previously suggested as possible influences on the course of depression and treatment effect, age and sex of the study population was not described in all articles. Other factors possibly influencing treatment effect, such as history of depression and of medication, were not reported in any of the studies. Finally, the numbers of potential confounders considered in the analyses, and the way in which their influence was evaluated, were marginal in some studies.
The diversity of designs is likely to have contributed to the observed heterogeneity of study results. Moreover, it cannot be excluded that other factors, such as differences in background genes between Asian and Caucasian subjects or differences in the cultural context of the diagnosis of depression and selection for treatment in different countries, have also influenced responsiveness to SSRI treatment. In view of the small number of studies, however, it is not possible to reliably identify specific determinants of study outcome.
In summary, the available evidence points to a somewhat less favourable effect of SSRIs among Caucasian patients with the s/s variant of the SERTPR polymorphism (as opposed to those with the s/l and l/ l variant) and among Asian patients with the 10/12 variant of the STin2 polymorphism (as opposed to those with the 12/12 variant). However, considering the heterogeneity of the studies with respect to population characteristics, type of intervention, and validity as well as the broad confidence intervals corresponding with the calculated RRs for the pooled response rates, accurate quantitative conclusions are presently out of reach. Therefore, it can currently not be recommended to implement testing on these polymorphisms prior to antidepressive treatment for selection of type or dose of medication. Future research, in order to be relevant for clinical practice, should report clearly on patient history (with respect to both medication and disease), patient recruitment, age, gender, ethnicity and type of blinding, and should evaluate the confounding influence of important determinants of treatment outcome. In the meantime, it would be worthwhile to evaluate what would be the minimum difference in treatment effect between genotypes to cost-effectively influence clinical practice; statistically significant, but relatively small, effects could be irrelevant for practice.
